RxDoctor Payments Data

Anju Lele, MD

Internal Medicine · Mentor, OHNPI 1558467423

Payments from drug & device makers

$11,354in general payments, 2019–2025

Across 698 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$1K
  • Novo Nordisk$805
  • Pfizer$580
  • Merck$547
  • GSK$517
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$11,354100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)77$1,248
Amgen(2 entities)56$1,067
Novo Nordisk57$805
Pfizer41$580
Merck33$547
GSK35$517
Boehringer Ingelheim31$494
AstraZeneca31$475
Lilly USA, LLC42$464
Astellas Pharma US Inc21$404
Lundbeck LLC11$322
E.r. Squibb & Sons, L.L.C.14$249
Xeris Pharmaceuticals, Inc.12$248
Otsuka America Pharmaceutical, Inc.9$238
Bayer16$229
Abbott11$225
Novartis13$208
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC14$194
Corcept Therapeutics13$191
Sanofi-aventis U.S. LLC10$181
Sunovion Pharmaceuticals Inc.13$180
Johnson & Johnson12$178
Axsome Therapeutics, Inc.8$151
Amarin Pharma, Inc.8$146
Sumitomo Pharma America, Inc.6$142
Vivus LLC7$129
Aimmune Therapeutics, Inc.6$125
Dexcom, Inc.4$101
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$91
Phathom Pharmaceuticals, Inc.19$88
Teva Pharmaceuticals USA, Inc.5$83
BETA Bionics, Inc.4$72
Takeda Pharmaceuticals U.S.A., Inc.5$71
Mylan Specialty L.p.3$70
Radius Health, Inc.5$68
Biohaven Pharmaceutical Holding Company Ltd.3$65
Hikma Pharmaceuticals USA4$58
Exact Sciences3$55
Mannkind Corporation2$52
Medtronic2$47
Bristol Myers Squibb2$41
Viatris Specialty LLC2$38
Nestle Healthcare Nutrition Inc.2$38
Idorsia Pharmaceuticals US Inc2$36
Scpharmaceuticals Inc.2$33
Cipher Pharmaceuticals US LLC1$31
Kowa Pharmaceuticals America, Inc.2$31
Insulet Corporation1$29
Evoke Pharma, Inc.2$28
Boston Scientific1$25
Scilex Pharmaceuticals Inc.1$21
Dynavax Technologies Corporation1$20
Eyevance Pharmaceuticals LLC1$18
UCB, Inc.1$18
Inspire Medical Systems, Inc.1$17
Ascensia Diabetes Care US Inc.1$15
Melinta Therapeutics, LLC1$15
Genentech USA, Inc.1$14
Neurocrine Biosciences, Inc.1$13
Supernus Pharmaceuticals, Inc.1$12

How this compares

$11,354 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$277,483
Medicare patients
526
Services billed
3,003

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban175$135,063
JanuviaSitagliptin Phosphate87$108,107
XareltoRivaroxaban70$83,909
OzempicSemaglutide45$47,182
MounjaroTirzepatide42$43,562
FarxigaDapagliflozin Propanediol27$30,437
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$20,292
TrulicityDulaglutide21$19,862
VraylarCariprazine Hcl17$18,215
SymbicortBudesonide/Formoterol Fumarate44$17,608
JardianceEmpagliflozin14$16,289
Spiriva RespimatTiotropium Bromide27$15,641
MyrbetriqMirabegron32$14,865
WegovySemaglutide11$14,602
Repatha SureclickEvolocumab14$14,448

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$580$137,921188 claims
MerckJanuvia$547$108,10787 claims
Johnson & JohnsonXarelto$178$83,90970 claims
Novo NordiskOzempic, Wegovy, Levemir$805$65,02067 claims
Lilly USA, LLCMounjaro, Trulicity$464$63,42463 claims
AstraZenecaFarxiga, Symbicort$475$48,04571 claims
GSKTrelegy Ellipta, Breo Ellipta$517$33,28165 claims
Boehringer IngelheimJardiance, Spiriva Respimat$494$31,93141 claims
AbbVieVraylar, Synthroid$1,248$21,05779 claims
Astellas Pharma US IncMyrbetriq$404$14,86532 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Mentor

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →